PAPER

Regional variations in the prevalence of multiple sclerosis in French farmers

Sandra Vukusic, Vincent Van Bockstael, Sophie Gosselin, Christian Confavreux

J Neurol Neurosurg Psychiatry 2007;**78**:707–709. doi: 10.1136/jnnp.2006.101196

See end of article for authors' affiliations

Correspondence to:
Dr Sandra Vukusic, Service de Neurologie A, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677 Lyon Bron Cedex, France; sandra.vukusic@chu-lyon.fr

Received 30 June 2006
Revised 31 January 2007
Accepted 6 February 2007
Published Online First
13 February 2007

Background: Studies on the prevalence of multiple sclerosis have been carried out worldwide, showing a heterogeneous distribution between countries and even between the different regions of the same country.

Methods: We estimated the regional and national prevalence of multiple sclerosis in France on 1 January 2003, based on the computerised database of the national farmer health insurance system ("Mutualité Sociale Agricole").

Results: There were 2667 cases of multiple sclerosis registered on the prevalence date, out of 4 098 477 affiliates. After standardisation on age, estimates for the national prevalence of multiple sclerosis in French farmers were 65.0 per 100 000 inhabitants (95% confidence interval 62.5 to 67.5), 41.9 per 100 000 in men (39.1 to 44.7) and 96.3 per 100 000 in women (92.0 to 100.6). The prevalence of multiple sclerosis was significantly higher in the north eastern regions (approximately 100 per 100 000 inhabitants) compared with the south western regions (around 50 per 100 000 inhabitants).

Conclusion: Our study is the first to evaluate the overall prevalence of multiple sclerosis in France and its 22 regions using the same methodology. Our results may be generalised to the whole French population as there is no convincing evidence of an increased or decreased susceptibility to multiple sclerosis among farmers or persons living in the countryside. This places France among the countries of medium to high prevalence. Confirming the uneven distribution of multiple sclerosis that correlates with latitude, raises once more the question of the role of genetic and environmental factors in the susceptibility to multiple sclerosis.

Studies on the prevalence of multiple sclerosis (MS) have been carried out worldwide, showing a heterogeneous distribution of cases between countries. This heterogeneity seems to correlate with latitude, with an increasing south to north gradient in the Northern hemisphere. Whether this gradient is caused by genetic or environmental factors remains a matter of debate.^{1–3} France is considered a country of medium to high prevalence for MS.^{4–8} To date, there has been no overall estimate of the prevalence of MS in France using the same methodology for all regions. The Mutualité Sociale Agricole is the second health insurance system in France. It has exclusive coverage of farmers and farm workers, as well as their spouses and children, provided they do not work outside the farm. Our objective was to estimate the overall prevalence of MS in France and in each of its 22 administrative regions.

METHODS

Source population

We studied the prevalence of MS on 1 January 2003, based on the computerised database of the Mutualité Sociale Agricole. In France, health insurance is a branch of the social security system. The active population is covered by statutory, occupation based, national health insurance schemes. All affiliates are automatically covered, as are the unemployed and the retired. The Mutualité Sociale Agricole is the second branch of social protection in France. It is a private professional organisation in charge of a public service mission, the management of the social risk of rural workers. It concerns farmers, salaried workers and their families. Its coverage among this population is complete and exclusive. When being affiliated, most of the general healthcare needs are partially reimbursed. The difference is generally covered by additional, private insurances. However, the treatment costs for those who suffer from chronic illnesses are completely reimbursed, provided the illness is on a list of the 30 admitted chronic diseases (Affections de Longue

Durée, ALD). MS is listed as ALD No 25. Once the diagnosis has been established by a neurologist, a detailed request is addressed to the health insurance system by the neurologist or the family doctor. Since the approval of disease modifying treatments, some of them approved after the first clinical episode, this request is often made as soon as MS is diagnosed. We searched in our database for all registered cases of MS on 1 January 2003.

Statistical analysis

The crude prevalence proportions were estimated for France and each of the 22 administrative regions. Estimates and structure by age and sex of the French population were provided by the Institut National de la Statistique et des Etudes Economiques for the same date.⁹ The population of farmers covered by the Mutualité Sociale Agricole is older than the French population. The distribution is however similar in terms of sex. Therefore, we provided estimates of the prevalence proportions after standardisation according to the structure by age, but not by sex.

A χ^2 trend test was performed to test the hypothesis of a north eastern to south western gradient, after dividing the 22 regions into three geographically defined zones, as shown in figure 1.

RESULTS

Overall prevalence of MS in France

On 1 January 2003, the Mutualité Sociale Agricole covered 4 098 477 persons, aged 49.9 (SD 25.8) years; 50% were women. There were 2667 cases of MS registered. Mean age was 54.9 (SD 14.5) years; 69% were women. The French population was 59 634 980 persons on the same date, aged 39 (23.2) years; 51% were women. After standardisation on age,

Abbreviations: ALD, Affections de Longue Durée; MS, multiple sclerosis

Figure 1 Estimates of the regional prevalence of multiple sclerosis on 1 January 2003, per 100 000 inhabitants, standardised by age, among French farmers.

estimates for the national prevalence of MS were 65.0 per 100 000 inhabitants (95% confidence interval 62.5 to 67.5), 41.9 per 100 000 in men (39.1 to 44.7) and 96.3 per 100 000 in women (92.0 to 100.6).

Prevalence of MS in the 22 administrative regions

Results are presented in table 1 and fig 1. The prevalence of MS was significantly higher in the north eastern (approximately 100 per 100 000 inhabitants) compared with the south western (approximately 50 per 100.000 inhabitants) regions, in the

overall population as well as in women or men separately ($p < 0.001$ for all comparisons).

DISCUSSION

Our study addressed the question of the overall prevalence of MS in France. It is the first to evaluate the prevalence in each region using the same methodology. We estimated that the standardised prevalence of MS in France was 65 per 100 000 inhabitants among French farmers. We also demonstrated the existence of an uneven geographical distribution, with a

Table 1 Estimates of the prevalence of multiple sclerosis in French farmers after standardisation on age, on 1 January 2003

Administrative region of France	Total population* (thousands)	No of affiliates to the MSA (% of general population)		No of MS patients declared to the MSA	Standardised prevalence of MS per 100 000 MSA affiliates [95% confidence interval]	Standardised prevalence of MS per 100 000 MSA affiliates according to sex	
		n	%			Men	Women
Picardie	1869	144 184	7.7%	139	103.2 [86.6–119.8]	62.8	144.0
Champagne	1337	145 713	10.9%	144	99.6 [83.4–115.8]	50.2	149.0
Lorraine	2319	99 714	4.3%	89	97.4 [78.0–116.8]	77.8	118.7
Franche-Comte	1130	76 401	6.8%	67	95.4 [73.5–117.3]	41.9	160.9
Nord	4013	146 435	3.6%	127	92.8 [77.2–108.4]	62.7	117.2
Ile de France	11 131	145 683	1.3%	98	88.2 [73.0–103.4]	49.5	123.1
Alsace	1775	64 701	3.6%	56	87.3 [64.5–110.1]	41.6	130.0
Centre	2467	224 891	9.1%	175	84.2 [72.2–96.2]	57.6	110.9
Haute-Normandie	1787	92 430	5.2%	68	82.5 [64.0–101.0]	54.9	99.8
Auvergne	1314	155 092	11.8%	115	78.4 [64.5–92.3]	38.6	123.5
Basse-Normandie	1436	172 675	12.0%	123	77.0 [63.9–90.1]	47.2	113.9
Limousin	711	96 912	13.6%	74	76.1 [58.7–93.5]	38.1	109.6
Rhone Alpes	5814	310 231	5.3%	193	70.5 [61.2–79.8]	34.7	102.4
Bourgogne	1612	154 516	9.6%	100	70.1 [56.9–83.3]	43.9	104.0
Bretagne	2978	355 636	11.9%	213	61.5 [53.4–69.6]	33.9	95.6
Pays de la Loire	3312	373 140	11.3%	207	59.3 [51.5–67.1]	25.1	97.3
Aquitaine	2988	338 856	11.3%	184	55.4 [47.5–63.3]	28.3	83.1
Languedoc-Roussillon	2402	242 211	10.1%	125	53.2 [44.0–62.4]	34.8	76.4
Corse	266	20 218	7.6%	9	53.0 [21.6–84.4]	56.2	52.6
Midi-Pyrenees	2638	296 663	11.2%	148	51.0 [42.9–59.1]	35.6	70.2
Provence Cote d'Azur	4666	222 320	4.8%	112	50.9 [41.5–60.3]	35.9	71.1
Poitou-Charentes	1668	219 855	13.2%	101	46.8 [37.8–55.8]	34.5	59.2
Total France	59 635	4 098 477	6.9%	2667	65.0 [62.5–67.5]	41.9	96.3

MS, multiple sclerosis; MSA, "Mutualité Sociale Agricole" (French farmer's national health insurance system).

*Source: INSEE (Institut National de la Statistique et des Etudes Economiques), estimates on 1 January 2003.

gradient in prevalence that decreased by 50%, from 100 per 100 000 inhabitants in the north east to 50 in the south west. The same general trend was observed separately for men and women.

These estimations sound robust, as the whole French rural population is covered by the same health insurance system, without any limitation on access to healthcare. The mean age of the farmer's population was 49.9 years (54.9 years for MS cases). The estimate is therefore unlikely to be biased because the disease has not yet appeared, as MS starts before the age of 40 years in more than 80% of patients.^{10–11} However, our figures may be underestimated. Report of MS as a long term illness to the health insurance system is usually conditioned by the need for treatment, either immunoactive or symptomatic. Early and benign cases may be missed by the system. This does not occur with more severe cases. This bias, however, is less in France because of the trend towards early prescription of disease modifying treatments.

Some patients may have changed their profession after the diagnosis of MS was established, for a less physically demanding occupation. In such cases, they would also have changed their insurance system. We have no precise data regarding this situation, which we consider to be rare. Ascertainment of cases may be discussed. Most of the MS cases are reported directly by neurologists, as neurologists are in charge of the diagnosis and are the only healthcare professionals allowed to prescribe approved immunoactive drugs in France. Some cases may be reported by general practitioners but usually after a diagnosis by a neurologist. Nevertheless, demonstration of the geographical gradient may be considered as very robust and reliable, as a differential declaration bias between the different regions would have been very unlikely.

Our results may be generalised to the whole of the French population, as there is no convincing evidence of increased or decreased susceptibility to MS among persons living in the countryside,³ apart from one positive association found in Norway between a rural inland residence and MS.¹² The north east to south west gradient we observed for France is similar to that previously described in other countries.^{1–3} Furthermore, our estimates are in accordance with those already available in France.^{2–4–7} In 1994, the main French health insurance system ("Régime général de la Sécurité Sociale") carried out a study of the prevalence of long lasting conditions, by random sampling of 2% of the patients declared as ALD.⁸ They estimated a prevalence rate of 40/100 000, which is lower than that reported in our study (65/100 000). However, there have been significant changes in reporting MS cases between 1994 and 2003, especially as a result of the introduction of immunoactive drugs for MS which are paid by the health insurance system. In 1994, the rule was to report only disabling cases, providing a systematic underestimation. The existence of a north to south gradient in the prevalence of MS in France had also been suggested previously from the systematic analysis of death certificates.⁴

Our results place France among countries of medium to high prevalence. Confirming the uneven distribution of MS raises the question of genetic and environmental factors in the risk of

developing MS. It has been suggested that the north to south gradient observed in the USA could rather match immigration patterns of Europeans at higher or lower risk of developing MS.¹³ However, migration studies in South Africa, Israel, the UK and French West Indies suggest that the prevalence of MS can also depend on the environment, as it may even vary within populations sharing the same genetic background, depending on the age at immigration.^{14–18}

ACKNOWLEDGEMENTS

The authors are indebted to Mr Laurent Laforest, Mrs Cécile Ritleng and Dr Eric Van Ganse for their help in the statistical analysis.

Authors' affiliations

Sandra Vukusic, Christian Confavreux, Service de Neurologie A and EDMUS Coordinating Centre, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France; INSERM U 842, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Lyon, France
Vincent Van Bockstael, Sophie Gosselin, Mutualité Sociale Agricole, Caisse Centrale, Bagnolet, France

Competing interests: None.

REFERENCES

- 1 Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part I and II. *Acta Neurol Scand* 1975;**51**:110–57.
- 2 Kurtzke JF, Delasnerie-Laupretre N. Reflection on the geographic distribution of multiple sclerosis in France. *Acta Neurol Scand* 1996;**93**:110–17.
- 3 Compston A, Confavreux C. The distribution of multiple sclerosis. In: Compston A, ed. *McAlpine's multiple sclerosis*, 4th Edn. London: Churchill Livingstone Elsevier, 2006:71–111.
- 4 Alperovitch A, Bouvier MH. Geographical pattern of death rates from multiple sclerosis in France. An analysis of 4912 deaths. *Acta Neurol Scand* 1982;**66**:454–61.
- 5 Gallou M, Madigand M, Masse L, et al. Epidémiologie de la sclérose en plaques en Bretagne. *Presse Med* 1983;**12**:995–9.
- 6 Confavreux CH, Darchy P, Alperovitch A, et al. Is south-eastern France a high risk area for multiple sclerosis [Le Sud-Est français, zone à «haut risque» de sclérose en plaques?]. *Presse Med* 1987;**16**:622–3.
- 7 Berr C, Puel J, Clanet M, et al. Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. *Acta Neurol Scand* 1989;**80**:46–50.
- 8 Fender P, Paita M, Gavray D, et al. Prevalence of thirty long term disorders for French health insurance members in 1994. *Rev Epidemiol Sante Publique* 1997;**45**:454–64.
- 9 Institut National de la Statistique et des Etudes Economiques. http://www.insee.fr/fr/ffc/pop_age2b.htm (accessed 24 April 2007).
- 10 Confavreux C, Compston A. The natural history of multiple sclerosis. In: Compston A, ed. *McAlpine's multiple sclerosis*, 4th Edn. London: Churchill Livingstone Elsevier, 2006:183–272.
- 11 Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. *N Engl J Med* 2000;**343**:1430–8.
- 12 Swank RL, Lerstad O, Strom A, et al. Multiple sclerosis in rural Norway, its geographic and occupational incidence in relation to nutrition. *N Engl J Med* 1952;**246**:721–8.
- 13 Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. *Clin Neurol Neurosurg* 2002;**104**:182–91.
- 14 Dean G. Annual incidence, prevalence and mortality of MS in white South African-born and in white immigrants to South Africa. *BMJ* 1967;**2**:724–30.
- 15 Alter M, Halpern L, Kurland LT, et al. Multiple sclerosis in Israel: prevalence among migrants and native inhabitants. *Arch Neurol* 1962;**7**:253–63.
- 16 Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age of immigration to Israel. *Arch Neurol* 1966;**15**:234–7.
- 17 Elian M, Nightingale S, Dean G. Multiple sclerosis among the United Kingdom born children of immigrants from the Indian subcontinent, Africa and the West Indies. *J Neurol Neurosurg Psychiatry* 1990;**53**:906–11.
- 18 Cabre P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. *Brain* 2005;**128**:2899–910.